Jonathan Jaffe, MD, Allergy & Immunology, Annandale, NJ


Allergy & Immunology Annandale, NJ

Clinical & Laboratory Immunology

Vice President for Clinical Development, Antares Pharma Inc.

Dr. Jaffe is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Jaffe's full profile

Already have an account?

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFELLOWSHIP
  • Lenox Hill Hospital
    Lenox Hill HospitalRESIDENCY
  • NYU School of Medicine
    NYU School of MedicineRESIDENCY
  • Abington Memorial HospitalINTERNSHIP
  • Sidney Kimmel Medical College
    Sidney Kimmel Medical CollegeMEDICAL_SCHOOL
  • Lehigh UniversityOTHER_TRAINING

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 1988 - 1992
  • NY State Medical License
    NY State Medical License 1985 - 2020
  • PA State Medical License
    PA State Medical License 1984 - 2016
  • American Board of Allergy and Immunology Allergy & Immunology
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Clinical & Laboratory Immunology

Awards, Honors, & Recognition

  • Pharma Development Business Excellence Award Novartis, 2007
  • Transplant and Immunology Business Excellence Award Novartis, 2006
  • Excellence Award Schering-Plough, 2002
  • Join now to see all

Publications & Presentations

Journal Articles

  • Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexat...  
    Schiff MH, Jaffe JS, Freundlich B, Ann Rheum Dis, 4/12/2014
  • In response to dosing omalizumab in allergic asthma  
    Jonathan S. Jaffe, Marc Massanari, The Journal of Allergy and Clinical Immunology, 1/1/2007
  • Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study  
    Nashan B, Curtis J, Ponticelli C, Mourad G, Jaffe J, Haas T, 156 Study Group, Transplantation, 11/15/2004
  • Join now to see all


  • A liquid formulation of omalizumab is bioequivalent to the current lyophilized formulation.
    G-J Riviere, P Kuebler, J. Jaffe, C. M Yeh, C. Reynolds L. Brookman, AJRCCM, 1/1/2008
  • The Effect of Discontinuing Omalizumab Therapy on Free IgE Concentration.
    P. Lowe, J. Jaffe, C. Martin, L. Brookman, H. Fox, The Journal of Allergy and Clinical Immunology, 1/1/2007
  • Everolimus In De Novo Pediatric Renal Transplantation: Results At 24 Months.
    R Ettenger , V M Moeller, P F Hoyer, J Lemire , J Mahan , N Webb , P Niaudet and J Jaffe, American Transplantation Congress, 1/1/2004
  • Join now to see all